Effectiveness of statins in people living with HIV: a systematic review and meta-analysis of randomized controlled trials

References

• Trickey A, May MT, Vehreschild J-J, et al. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–e356.
   PubMed Web of Science ®Google Scholar
• Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622.
   PubMed Web of Science ®Google Scholar
• Chen L, Pan X, Ma Q, et al. HIV cause-specific deaths, mortality, risk factors, and the combined influence of HAART and late diagnosis in Zhejiang, China, 2006–2013. Sci Rep. 2017;7(1):42366. doi: 10.1038/srep42366
   PubMedGoogle Scholar
• Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-Infected adults. J Infect Dis. 2012;205(Suppl 3):S375–82. doi: 10.1093/infdis/jis200
   PubMed Web of Science ®Google Scholar
• da Cunha J, Maselli LM, Stern AC, et al. Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: old and new drugs. WJV. 2015 May 12;4(2):56–77.
   Google Scholar
• Shah ASV, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis. Circulation. 2018;138(11):1100–1112. doi: 10.1161/CIRCULATIONAHA.117.033369
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Armon C, Buchacz K, et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis. 2010;51(4):435–447. doi: 10.1086/655144
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society. EACS Guidelines [10.0]. 2019. https://www.eacsociety.org/media/2019_guidelines-10.0_final.pdf
   Google Scholar
• Rosenson RS, Colantonio LD, Burkholder GA, et al. Trends in utilization of statin therapy and contraindicated statin use in HIV‐‐infected adults treated with antiretroviral therapy from 2007 through 2015. JAHA. 2018 Dec 18;7(24). doi: 10.1161/JAHA.118.010345
   Google Scholar
• Stein JH, Hsue PY. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA. 2012;308(4):405–406. doi: 10.1001/jama.2012.8488
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Panza G, Zaleski A, et al. Statin-associated side effects. J Am Coll Cardiol. 2016;67(20):2395–2410. doi: 10.1016/j.jacc.2016.02.071
   PubMed Web of Science ®Google Scholar
• Aberg JA, Sponseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV. 2017;4(7):e284–e294. ISSN 2352-3018. doi: 10.1016/S2352-3018(17)30075-9
   PubMed Web of Science ®Google Scholar
• Zanetti HR, Gonçalves A, Teixeira Paranhos Lopes L, et al. Effects of exercise training and statin use in people living with human immunodeficiency virus with dyslipidemia. Med Sci Sports Exerc. 2020;52(1):16–24. doi: 10.1249/MSS.0000000000002120
   PubMed Web of Science ®Google Scholar
• Eckard AR, Cho S, O’Riordan MA, et al. Kallistatin levels in HIV-infected patients and effects of statin therapy. Biomarkers. 2017;22(1):55–62. doi: 10.1080/1354750X.2016.1204002
   PubMed Web of Science ®Google Scholar
• Dirajlal-Fargo S, Kinley B, Jiang Y, et al. Statin therapy decreases N-terminal pro-B-type natriuretic peptide in HIV: randomized placebo-controlled trial. AIDS. 2015;29(3):313–321. doi: 10.1097/QAD.0000000000000547
   PubMed Web of Science ®Google Scholar
• Trevillyan JM, Dart A, Paul E, et al. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial. AIDS. 2021;35(4):619–624. doi: 10.1097/QAD.0000000000002764
   PubMed Web of Science ®Google Scholar
• Hearps AC, Angelovich TA, Trevillyan JM, et al. Effect of rosuvastatin therapy on biomarkers of inflammation and immune activation in people with human immunodeficiency virus at intermediate cardiovascular risk. J Infect Dis. 2021;224(4):667–672. doi: 10.1093/infdis/jiaa775
   PubMed Web of Science ®Google Scholar
• Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209(8):1156–1164. doi: 10.1093/infdis/jiu012
   PubMed Web of Science ®Google Scholar
• Longenecker CT, Sattar A, Gilkeson R, et al. Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS. 2016;30(14):2195–2203. doi: 10.1097/QAD.0000000000001167
   PubMed Web of Science ®Google Scholar
• Mallon PW, Miller J, Kovacic JC, et al. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men–a randomized, placebo-controlled study. AIDS. 2006;20(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Aurillac-Lavignolle V, Breilh D, et al. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials. 2007;8(1):53–60. doi: 10.1310/hct0801-53
   PubMed Web of Science ®Google Scholar
• Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52–e63. doi: 10.1016/S2352-3018(14)00032-0
   PubMed Web of Science ®Google Scholar
• Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687–699. doi: 10.1056/NEJMoa2304146
   PubMed Web of Science ®Google Scholar
• Montoya CJ, Higuita EA, Estrada S, et al. Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305). J Infect. 2012;65(6):549–558. doi: 10.1016/j.jinf.2012.10.016
   PubMed Web of Science ®Google Scholar
• Nou E, Lo J, Hadigan C, et al. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol. 2016 Jul;4(7):598–610.
   PubMed Web of Science ®Google Scholar
• Abutaleb A, Feinstein MJ Coronary artery disease in HIV [Internet]. American College of Cardiology. 2018 [cited 2023 Nov 11]. Available from: https://www.acc.org/Latest-in-Cardiology/Articles/2018/01/18/08/57/Coronary-Artery-Disease-in-HIV#:~:text=People%20living%20with%20HIV%20have
   Google Scholar
• Lacson JCA, Barnes RP, Bahrami H. Coronary artery disease in HIV-infected patients: downside of living longer. Curr Atheroscler Rep. 2017 Apr 1;19(4):18. InternetAvailable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066371/
   PubMed Web of Science ®Google Scholar
• Bahrami H, Budoff M, Haberlen SA, et al. Inflammatory markers associated with subclinical coronary artery disease: the multicenter AIDS cohort study [Internet]. J Am Heart Assoc. 2016 Jun 27;5(6):e003371. doi: 10.1161/JAHA.116.003371
   PubMed Web of Science ®Google Scholar
• Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6–14. doi: 10.1016/j.jcte.2017.01.004
   PubMedGoogle Scholar
• Moore RD, Bartlett JG, Gallant JE, et al. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLOS ONE. 2011;6(7):e21843. doi: 10.1371/journal.pone.0021843
   PubMed Web of Science ®Google Scholar
• Eckard AR, McComsey GA. The role of statins in the setting of HIV infection. Curr HIV/AIDS Rep. 2015;12(3):305–312. doi: 10.1007/s11904-015-0273-9
   PubMed Web of Science ®Google Scholar
• Banach M, Dinca M, Ursoniu S, et al. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res. 2016 Sep [Epub 2016 Jun 25]; 111:343–356. doi: 10.1016/j.phrs.2016.06.005
   PubMed Web of Science ®Google Scholar
• Mokgalaboni K, Phoswa WN, Yates S, et al. A systematic review and meta-analysis on the impact of statin treatment in HIV patients on antiretroviral therapy. Int J Environ Res Public Health. 2023 Apr 27;20(9):5668. doi: 10.3390/ijerph20095668
   PubMedGoogle Scholar
• Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014;96(4):470–476. doi: 10.1038/clpt.2014.121
   PubMed Web of Science ®Google Scholar
• Vigny NN, Bonsu KO, Kadirvelu A. Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis. Sci Rep. 2022 Oct 27;12(1):18121. doi: 10.1038/s41598-022-23102-2
   PubMed Web of Science ®Google Scholar
• Gili S, Grosso Marra W, D’Ascenzo F, et al. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. Eur Heart J. 2016 Dec 21 [Epub 2016 Feb 6];37(48):3600–3609. doi: 10.1093/eurheartj/ehv734
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. ATVB. 2019 Feb;39(2). doi: 10.1161/ATV.0000000000000073
   Google Scholar
• Al Sayed HAH, Sharif-Askari NS, Rahimi MR. Clinically significant drug interactions between antiretroviral and co-prescribed drugs in HIV infected patients: retrospective cohort study. Med Pharm Rep. 2022;95(3):260–266. doi: 10.15386/mpr-2305
   PubMedGoogle Scholar
• Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16(4):569–577. doi: 10.1097/00002030-200203080-00008
   PubMed Web of Science ®Google Scholar
• Ladapo JA, Richards AK, DeWitt CM, et al. Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. JAHA. 2017;6(11):e007107. doi: 10.1161/JAHA.117.007107
   Google Scholar
• Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021;374:n1537. doi: 10.1136/bmj.n1537
   PubMed Web of Science ®Google Scholar
• Baker JV, Huppler Hullsiek K, Prosser R, et al. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.PLOS ONE. 2012;7(10):e46894. doi: 10.1371/journal.pone.0046894
   PubMed Web of Science ®Google Scholar